Galera, which has about 30 employees, had as of Sept. 30 cash and cash equivalents of $42.8 million as of Sept. 30. — which it expects will enable the company to fund its operating expenses and ...

Galera reported a net loss of $4.1 million, or $0.07 per share, for the second quarter of 2024, compared to a net loss of $20.7 million, or $0.48 per share, in the same period in 2023.

Galera Therapeutics is shuttering, with the biotech’s board OK'ing a liquidation plan that whittles down the company’s workforce to just three people. The clinical-stage company—which was ...

Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer.

The vote to dissolve Galera came after no other “suitable options” for the company could be found. During the dissolution process, the company will pursue the sale of its drug candidate assets.